Compare
Caribou Biosciences, Inc. vs TScan Therapeutics, Inc. vs Alpha Cognition Inc. vs Taysha Gene Therapies, Inc.
| Latest fiscal year | Caribou Biosciences, Inc. CRBU | TScan Therapeutics, Inc. TCRX | Alpha Cognition Inc. ACOG | Taysha Gene Therapies, Inc. TSHA |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $11.16M | $10.32M | $10.22M | $9.77M |
| Revenue growth (YoY) | +11.7% | +266.7% | n/a | +17.3% |
| Gross margin | n/a | n/a | 94.1% (computed) | n/a |
| Operating margin | n/m | n/m | -221.7% | n/m |
| Net margin | n/m | n/m | -202.2% | n/m |
| Net income | -$148.12M | -$129.77M | -$20.67M | -$109.00M |
| EPS (Diluted) | -$1.59 | -$1.00 | -$1.18 | -$0.34 |
| Operating cash flow | -$110.99M | -$135.32M | -$20.38M | -$93.09M |
| Free cash flow | -$112.35M | -$139.73M | -$20.67M | -$93.83M |
| Cash & equivalents | $12.36M | $152.41M | $66.05M | $319.77M |
| Total assets | $175.37M | $228.79M | $79.73M | $343.32M |
| Total liabilities | $53.19M | $105.67M | $17.20M | $96.38M |
| Shareholders' equity | $122.17M | $123.12M | $62.53M | $246.94M |
| Return on year-end equity | -121.2% | -105.4% | -33.1% | -44.1% |
| Shares outstanding | 95.14M | n/a | 21.74M | 285.05M |
Revenue, most recent five fiscal years
| Fiscal year | Caribou Biosciences, Inc. | TScan Therapeutics, Inc. | Alpha Cognition Inc. | Taysha Gene Therapies, Inc. |
|---|---|---|---|---|
| Latest | $11.16M Ended 2025-12-31 | $10.32M Ended 2025-12-31 | $10.22M Ended 2025-12-31 | $9.77M Ended 2025-12-31 |
| 1 year earlier | $9.99M Ended 2024-12-31 | $2.82M Ended 2024-12-31 | n/a | $8.33M Ended 2024-12-31 |
| 2 years earlier | $34.48M Ended 2023-12-31 | $21.05M Ended 2023-12-31 | n/a | $15.45M Ended 2023-12-31 |
| 3 years earlier | $13.85M Ended 2022-12-31 | $13.54M Ended 2022-12-31 | n/a | $2.50M Ended 2022-12-31 |
| 4 years earlier | $9.60M Ended 2021-12-31 | $10.14M Ended 2021-12-31 | n/a | n/a |